News | Magnetic Resonance Imaging (MRI) | October 26, 2020

ASTRO 2020 to Feature Latest MRIdian Clinical Experience Highlighting Outcomes in Tough to Treat Cancer

Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions

Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions

October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will be featured at the 2020 Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held virtually October 24 to 28, 2020. The meeting will feature presentations that showcase the MRIdian system, including how clinicians use this cutting-edge Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) technology to tackle both tough-to-treat and ubiquitous cancer, expand clinical experience with the device, and impact patient outcomes.

At this year's virtual ASTRO meeting, nearly 40 scientific session presentations/posters will highlight the important role of MRIdian in cancer care, including data bolstering its clinical value in the treatment of pancreas, prostate and tough-to-treat tumors such as oligometastases and renal cancer. With the clarity provided by MRIdian's real-time imaging and automatic beam gating, physicians are equipped to account for anatomical changes and motion caused by respiration or other bodily processes to personalize treatment to the patient's unique needs.

  • Acibadem Maslak Hospital will present its data on MRIdian treatment for low- to intermedia-risk prostate cancer patients. This study complements the Amsterdam University Medical Centers studies on patients with intermediate- to high-risk prostate cancer, where no fiducials were required and which resulted in fewer grade 2 toxicities than published data*.
  • Weill Cornell/NewYork-Presbyterian, the Miami Cancer Institute (MCI), and the Moffitt Cancer Institute are among the institutions presenting on their experiences using SMART for pancreas cancer. Findings are expected to strengthen the current body of literature, with SMART helping clinicians drive positive patient outcomes and new insights on volumes and survivability.
  • Amsterdam University Medical Centers and MCI will share data on utilization of SMART for tough-to-treat tumors, including renal cancer and abdominal oligomets, treated with radiation therapy and immunotherapy. 

As part of ASTRO's Innovation Hub, a dedicated space within the virtual platform to highlight new technologies and innovations, ViewRay will host two brief Innovation Hub presentations on MRIdian's capabilities and a presentation on workflow and efficiency by Justin Rineer, M.D., Radiation Oncologist at Orlando Health UF Health Cancer Center. The company will also host an Industry Expert Theater presentation featuring experts from the Dana -Farber/Brigham Women's Cancer Center discussing their MRIdian clinical experience:

To visit ViewRay's virtual booth and for a full schedule of the MRIdian-focused presentations at ASTRO 2020 please visit https://viewray.com/events-webinars. ViewRay's booth will feature information including:

  • Experience MRIdian: Treat and Prove what Others Can't (Demo and more)
  • The Patient Experience: Latest Videos
  • Innovation Value: See What's New with Technology and Treatment
  • Clinical Value: See the Results
  • MRIdian in Action: Learn More About our Customer Experience
  • The Economic Value of MRIdian: The Financial Benefits of Introducing a New Service Line

Additionally, ViewRay will host a physician-led webinar for investors and analysts on Tuesday, October 27, 2020 at 11:00 am ET. Registration is required to attend and will close an hour prior to the start. Please register at https://www.bigmarker.com/viewray/Physician-led-Webinar-for-Investors-and-Analysts-at-2020-ASTRO-Annual-Meeting?utm_bmcr_source=Press.

Currently 40 MRIdian systems are installed at hospitals around the world, where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. More than 10,000 patients have been treated with MRIdian. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/

* Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016 Aug;17(8):1047-10.

Related Content

ASG well positioned for growth as healthcare marketplace continues to evolve 

Allan Klotsche

News | Radiology Imaging | November 24, 2020
November 24, 2020 — Alpha Source Group (ASG), a comprehensive next-generation services partner, has named...
1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well

1H-MR spectra of 3 consecutive patients with COVID-19. Upper row: Axial FLAIR images at the corona radiata level show representative MRS voxels (black squares) from sampled periventricular regions. Lower row: Corresponding spectrum (black) and LCModel fit (red) from each patient acquired at TE = 30 ms (upper row) and TE = 288 ms (lower row). A, A patient with COVID-19-associated multifocal necrotizing leukoencephalopathy shows diffuse patchy WM lesions with markedly increased Cho and decreased NAA, as well as elevated Lac. B, A patient with COVID-19 after recent PEA cardiac arrest with subtle FLAIR hyperintense white matter changes also shows elevated Cho/Cr and decreased NAA/Cr ratios. However, these derangements are less severe than in the patient in A. There is no clear elevation of Lac. C, A patient with COVID-19 without encephalopathy or recent severe hypoxia has normal Cho/Cr, with mildly decreased NAA/Cr and no lactate elevation. Cho, Choline; NAA, N-Acetyl-Aspartate; mI, Myo-Inositol; Lac, Lactate; Glx, Glutamate + Glutamine. Image courtesy of AJNR

News | Coronavirus (COVID-19) | November 19, 2020
November 19, 2020 — One of the first spectroscopic imaging-based studies of neurological injury in...
During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

Getty Images

News | Prostate Cancer | November 18, 2020
November 18, 2020 — ...
SyntheticMR, an innovative software solutions company for magnetic resonance imaging (MRI) announced today the company filed a 510(k) submission for its musculoskeletal solutions package, SyMRI MSK.
News | Magnetic Resonance Imaging (MRI) | November 17, 2020
November 17, 2020 — SyntheticMR, an innovative software solutions company for...